Payer Coverage Tracking
Coverage tracking maintains current formulary position, tier placement, and restriction status across plans, which changes continuously and is rarely centrally known.
Custom Software
Pharma Market Access Analytics Development
Market access analytics platforms track payer coverage and formulary position, quantify access barriers, support health economics evidence, and provide gross-to-net visibility. Because gross-to-net figures feed financial reporting, those calculations carry control requirements that ordinary commercial analytics do not.
Market access sits between commercial performance and financial reporting, which gives its analytics an unusual dual character: the same rebate and chargeback data informs contracting strategy and revenue recognition. Taction Software builds pharma market access analytics where that distinction is respected, with controls applied where numbers reach financial statements.
Tell Us Your Requirements
Our experts are ready to understand your business goals.
Trusted Partners
Trusted by Industry Leaders Worldwide
Recognition
Awards & Recognitions
What Is Market Access Analytics
Pharma market access analytics consolidates payer coverage status, formulary placement, utilization management restrictions, rejected and abandoned claims, contract performance, and gross-to-net components into analysis supporting access strategy. It answers questions commercial analytics cannot: whether prescriptions are written but not filled, where prior authorization blocks therapy, and what net realized price actually is after rebates and fees. Our work sits within our broader pharma and life sciences practice.
Formulary and Restriction Analytics
Utilization management analysis quantifies where prior authorization and step therapy requirements affect access, by plan and therapeutic area.
Access Barrier Quantification
Abandonment analysis identifies where prescriptions are written but never filled, which is invisible in prescription data alone.
HEOR Evidence Management
HEOR evidence organization supports value communication, drawing on our real world evidence platform work for outcomes data.
Contract Performance Analytics
Contract performance measures whether negotiated access and volume commitments are materializing, informing renewal and renegotiation decisions.
Gross-to-Net Visibility
Gross-to-net analysis tracks rebates, discounts, and fees against gross sales, with controls appropriate to figures feeding financial reporting.
Core Market Access Analytics Services
Our pharma market access analytics services cover data integration, coverage tracking, analytics delivery, evidence platforms, and gross-to-net reporting. The engineering challenge is data breadth: access analysis requires claims data, coverage files, contract terms, and rebate accruals from sources that were never designed to reconcile. Engagements typically open with an assessment of available data and where current reporting produces disagreement between access, finance, and commercial teams.
01
Access Data Integration
We integrate claims, coverage, and contract data, reconciling sources with differing plan definitions and effective dates into consistent analysis.
02
Data Platform Foundation
Platform work builds on our healthcare data warehouse practice, with dimensional modeling handling time-variant coverage status.
03
Cloud Data Engineering
Large claims datasets use Snowflake or comparable platforms for scalable processing where volume warrants.
04
Coverage Tracking Systems
Coverage tracking maintains formulary status across plans with effective dating, since access status changes and historical position matters for analysis.
05
Contract Data Management
Contract terms integration draws on our healthcare contract management work for term structuring and performance measurement.
06
Analytics and Reporting Delivery
Reporting uses Microsoft Power BI or your existing stack, with access dashboards built for the decisions access teams actually make.
Benefits of Market Access Analytics
The benefits concentrate in coverage visibility, quantified access barriers, and reliable net price understanding. Access teams frequently operate without a current picture of coverage across plans, which makes contracting decisions less informed than they should be. Abandonment analysis also reveals losses invisible in prescription data. We publish no figures on access improvement, formulary wins, or net price optimization, because those depend entirely on product, therapeutic area, and payer landscape.
Current Coverage Picture
Consolidated formulary status across plans replaces fragmented knowledge held by individual account directors in personal spreadsheets.
Quantified Access Barriers
Barrier analysis measures where prior authorization and step therapy affect fills, converting anecdote into evidence for contracting discussions.
Visible Abandonment
Abandonment tracking shows prescriptions written but never filled, revealing losses that prescription-based commercial reporting cannot detect.
Better Contract Decisions
Performance measurement against contract terms informs renewal, showing whether negotiated access actually produced the expected utilization.
Reliable Net Price
Gross-to-net visibility gives commercial and finance a shared view of realized price, reducing the reconciliation friction between those functions.
Evidence Readiness
Organized HEOR evidence supports payer discussions, with communication governed by the rules applying to pre-approval and on-label exchange.
Our Market Access Analytics Process
We deliver pharma market access analytics projects in gated phases so access, finance, and IT stakeholders approve direction before engineering cost accumulates. Discovery establishes data availability, current reporting conflicts, and which outputs feed financial reporting, since those require stronger controls. Development is iterative with access team review. We separate operational analytics from gross-to-net reporting deliberately, because mixing exploratory analysis with controlled financial figures creates audit difficulty.
Discovery and Data Assessment
Discovery evaluates data availability across claims, coverage, and contract sources, and identifies where current reporting produces cross-functional disagreement.
Financial Control Boundary
We identify which outputs feed financial reporting, since gross-to-net figures require controls that exploratory analytics do not.
Coverage Model Design
Effective dating is designed into the coverage model, since analyzing past performance requires knowing formulary status as it was, not as it is now.
Integration Development
Integration reconciles plan definitions across sources, which differ in identifiers and hierarchy and produce silent mismatches when assumed equivalent.
Analytics Delivery
Dashboards are built with access teams, prioritizing contracting and account decisions rather than reproducing every available metric.
Rollout and Ongoing Operations
Rollout expands by function with data quality monitoring and continuing support as payer landscape, contracts, and data sources change.
Technology and Compliance
Market access analytics uses licensed claims data under contractual restrictions, contract terms carrying confidentiality obligations, and gross-to-net figures feeding financial reporting subject to internal control requirements. Manufacturers are generally not HIPAA covered entities, and patient-level claims data is licensed de-identified. Taction holds ISO 27001 certification. Two requirements deserve emphasis: gross-to-net calculations need auditable controls because they affect revenue recognition, and payer value communication operates under rules governing what evidence may be shared and when.
Financial Reporting Controls
Gross-to-net calculations feed revenue recognition, requiring auditable logic, change control, and reconciliation rather than analyst-maintained spreadsheets.
Data License Compliance
License terms on claims data restrict usage and combination, enforced technically rather than left to analyst discretion in ad hoc analysis.
Payer Communication Rules
Value communication to payers operates under specific rules governing evidence exchange, which the platform supports rather than determines.
Contract Confidentiality
Contract terms carry confidentiality obligations, requiring access controls preventing exposure across accounts or to unauthorized internal users.
Privacy Framework Accuracy
Claims data is licensed de-identified and manufacturers are generally not covered entities. Our HIPAA compliance practice explains the boundary.
Deployment Security
Deployments run in your cloud tenancy or hybrid, with network segmentation, signed container images, and documented penetration testing before release.
Why Choose Taction Software
Taction Software was founded in 2013 and has spent over 12 years building healthcare and life sciences software, delivering more than 200 healthcare projects from four US offices in Chicago, Cheyenne, Austin, and Sacramento, with ISO 27001 certification. Our relevant discipline here is separating controlled financial reporting from exploratory analytics. Mixing them produces platforms where nobody can explain how a reported number was derived, which becomes a problem during audit rather than during analysis. Our leadership brings more than 20 years of personal experience in the field.
01
Financial and Analytical Separation
We separate controlled reporting from exploratory analysis, since gross-to-net figures need auditable derivation that ad hoc analytics cannot provide.
02
Effective Dating Discipline
We model coverage history with effective dating, since analyzing past performance against current formulary status produces confidently wrong conclusions.
03
Established Healthcare Focus
Founded in 2013, we have concentrated on healthcare and life sciences rather than treating them as one vertical among several.
04
Data Engineering Depth
We reconcile plan definitions across claims, coverage, and contract sources, which is where market access analytics projects most often stall.
05
Vendor Neutrality
We make no partnership claims about data or analytics vendors, recommending the stack fitting your environment rather than one we resell.
06
Certified Security Posture
ISO 27001 certification means security controls are documented and auditable, supporting pharmaceutical vendor assessment efficiently.
Pricing
Pharma market access analytics pricing depends on scope, data source count, whether gross-to-net reporting is included, and contract portfolio complexity. Gross-to-net work carries additional control and documentation requirements that raise cost relative to purely analytical scope. Data subscriptions are a substantial separate cost paid to data vendors. Discovery produces an itemized, fixed-scope estimate with phase-level breakdown. Cloud infrastructure and platform licensing are separate and itemized clearly.
MVP or Single Module
An MVP delivering coverage tracking and formulary reporting typically runs $40,000 to $80,000, establishing visibility before deeper analytics.
Full Platform Build
A full platform with claims integration, barrier analysis, contract performance, and evidence management typically falls between $80,000 and $200,000.
Enterprise Deployment
Enterprise engagements covering gross-to-net reporting with financial controls and multi-product portfolios start at $200,000.
Discovery Phase Scoping
Discovery is a paid, time-boxed phase producing an itemized estimate, architecture plan, and financial control boundary assessment.
Cost Drivers to Expect
Gross-to-net scope, data source count, contract complexity, and product count are the largest variables, identified during discovery.
Ongoing Support Costs
Post-launch data operations, coverage file updates, contract changes, and support are quoted separately as a retainer sized to portfolio breadth.
Get Started
If you are evaluating pharma market access analytics for coverage tracking, barrier quantification, contract performance, or gross-to-net visibility, the fastest next step is a discovery call with our team. We will assess data availability, identify which outputs need financial controls, and return an itemized, fixed-scope estimate. Contact us to schedule that conversation.
FAQs
Frequently Asked Questions
Access and finance leaders evaluating pharma market access analytics usually ask about gross-to-net controls, coverage data currency, and why access reporting disagrees with commercial reporting. The answers below reflect how we scope these projects.
Because those figures feed revenue recognition, which means the derivation must be auditable and change-controlled. Analytics built for exploration lets users adjust logic freely, which is appropriate for analysis and unacceptable for reported financials. We separate the two rather than applying one standard to both.
Less current than teams expect. Formulary changes are published on varying schedules and payer coverage files lag actual policy changes. We build effective dating so analysis reflects status as it was at the time, and we surface data currency rather than presenting stale coverage as current fact.
Usually because they measure different things from different sources. Commercial measures prescriptions written; access measures prescriptions filled and reimbursed. The gap is abandonment and rejection, which is genuine signal rather than error, and quantifying it is often the most valuable output of the platform.
An MVP with coverage tracking runs $40,000 to $80,000. A full platform typically falls between $80,000 and $200,000. Enterprise deployments with controlled gross-to-net reporting start at $200,000. Data subscriptions are paid to your data vendors separately.
It can organize and manage HEOR evidence, which supports communication conducted under the applicable rules governing what may be shared with payers and when. The platform manages evidence; your medical and legal teams determine what communication is permissible in each context.
Generally not directly, since manufacturers are typically not covered entities and patient-level claims are licensed in de-identified form. License terms and re-identification prohibitions govern instead, and we enforce those technically rather than relying on analyst discretion.